Navigation Links
Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue
Date:2/3/2011

ysicians in over 55 countries had ordered more than 175,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional stages of breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to generate similar results in further studies, the clinical utility of preliminary biomarkers; our ability to develop whole transcriptome and/or genome expression analysis for routine clinical study; the belief that whole genome expression may accelerate clinical or biomarker discovery; our ability to develop, validate or commercialize advanced diagnostics based upon such genome expression data; the  timing of such studies and results; and the company's ability to accelerate its research and development efforts to move whole genome expression technology into clinical studies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the applicability of clinical study results to actual outcomes; the risks and potential delays associated with such studies; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. These forward-looking statements speak only as of the date hereof.
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
2. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
3. Rosetta Genomics Reports Second Quarter 2008 Financial Results
4. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
5. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
6. Brewing better beer: Scientists determine the genomic origins of lager yeasts
7. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
8. As personalized, genomic medicine takes off, four developing countries show the way for others
9. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
10. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
11. TIBCO Spotfire and INTEGROMICS Announce Genomics Data Analysis Solution to Radically Speed Drug Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... 2012  Barbara Walters, Kevin Bacon, Kyra Sedgwick, Wanda Sykes ... in the PBS series Finding Your Roots with ... scientific help of leading personal genetics company, 23andMe.  23andMe ... Your Roots and consulted with show producers to ...
... company Innovative Carbon Limited today announces that they will be ... Graphene, a sheet of carbon just one atom thick, has ... at Manchester University in 2004, for which the team was ... produce it commercially. To support this work the UK ...
... 2012 Arteriocyte, a leading biotechnology company with ... today approval from the Food and Drug Administration ... using its Magellan MAR01™ technology in the treatment ... (IDE 15013) allows Arteriocyte and its clinical partners ...
Cached Biology Technology:23andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service® 223andMe Provides the Science Behind PBS Series "Finding Your Roots with Henry Louis Gates, Jr." With Its Personal Genome Service® 3UK company to demonstrate their commercially effective graphene production process 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... University (Canada) have teamed up with genome researchers from ... bone samples from Siberia. The project also involved ... and researchers from Russia, the United Kingdom, France, and ... sequences from a woolly mammoth will be published on ...
... the first solid evidence that still "sharp" older brains store ... discovery is reported by a Johns Hopkins team in the ... prove to apply as well to human brains, it could ... therapies based on what healthy older brains are doing, rather ...
... Unscripted biochemical variations, or noise, leads to oscillations in ... have debated for decades the relative importance of nature ... behaves, and now UCSD scientists report that noise could ... , In a paper in Proceedings of the National ...
Cached Biology News:Scientists sequence DNA of woolly mammoth 2'Sharp' older brains are not the same as younger brains 2Phenotype is influenced by nature, nurture and noise 2